SCOPUS 정보 검색 플랫폼

Community Oncology

Volumn 4, Issue 3, 2007, Pages 121-122

Panitumumab in metastatic colorectal cancer

(1) Abraham, Jame a

a WEST VIRGINIA UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UNCLASSIFIED DRUG; VECTIBIX;

CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERYTHEMA; FATIGUE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; METASTASIS; NAUSEA; PARONYCHIA; PRURITUS; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

EID: 34147139931 PISSN: 15485315 EISSN: None Source Type: Journal
DOI: 10.1016/S1548-5315(11)70067-5 Document Type: Conference Paper

Times cited : (1)

References (6)

1
- 33749032101
- Role of panitumumab in the management of metastatic colorectal cancer
- Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:118-124.
- (2006) Clin Colorectal Cancer , vol.6 , pp. 118-124
- Saif, M.W.¹ Cohenuram, M.²

2
- 33745917044
- Panitumumab: A new anti-EGFR antibody for the treatment of advanced colorectal cancer [editorial]
- Chu E. Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer [editorial]. Clin Colorectal Cancer 2006;6:13.
- (2006) Clin Colorectal Cancer , vol.6 , pp. 13
- Chu, E.¹

3
- 33749015088
- A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer
- Presented at the, April 1-5, Washington, DC. Abstract CP-1
- th Annual Meeting of the American Association of Cancer Research, April 1-5, 2006; Washington, DC. Abstract CP-1.
- (2006) th Annual Meeting of the American Association of Cancer Research
- Peeters, M.¹ van Cutsem, E.² Siena, S.³

4
- 33847694798
- Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC)
- Presented at the, January 26-28, San Francisco, Calif. Abstract 237
- Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at the 2006 Gastrointestinal Cancers Symposium, January 26-28, 2006; San Francisco, Calif. Abstract 237.
- (2006) 2006 Gastrointestinal Cancers Symposium
- Hecht, J.¹ Posey, J.² Tchekmedyian, S.³

5
- 33244473097
- A phase III, randomized, open-label, controlled trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
- Wainberg Z, Hecht JR. A phase III, randomized, open-label, controlled trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5:363-367.
- (2006) Clin Colorectal Cancer , vol.5 , pp. 363-367
- Wainberg, Z.¹ Hecht, J.R.²

6
- 85039194090
- Safety and pharmacokinetics (PK) of AMG 706 with panitumumab and FOLFIRI for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)
- Presented at the, January 26-28, San Francisco, Calif. Abstract 354
- Burris HA, Stephenson J, Hurwitz H, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab and FOLFIRI for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). Presented at the 2006 Gastrointestinal Cancers Symposium, January 26-28, 2006; San Francisco, Calif. Abstract 354.
- (2006) 2006 Gastrointestinal Cancers Symposium
- Burris, H.A.¹ Stephenson, J.² Hurwitz, H.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.